Group 1 - The core point of the news is that Yinosh experienced a decline of 5.01% in its stock price, closing at 66.00 CNY per share, with a trading volume of 198 million CNY and a turnover rate of 3.17%, resulting in a total market capitalization of 9.305 billion CNY [1] - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing comprehensive research and development services (CRO) primarily focused on non-clinical research services [1] - The revenue composition of Yinosh is heavily weighted towards non-clinical services, accounting for 96.31%, while clinical services contribute 3.42% and other services make up 0.27% [1] Group 2 - From the perspective of Yinosh's top ten circulating shareholders, Huaxia Fund has a fund that ranks among the top shareholders, specifically Huaxia Stable Growth Mixed Fund (005450), which entered the top ten in the third quarter with 930,500 shares, representing 1.03% of the circulating shares [2] - The estimated floating loss for Huaxia Stable Growth Mixed Fund today is approximately 3.2381 million CNY [2] - The fund was established on January 17, 2018, with a current scale of 1.09 billion CNY, achieving a year-to-date return of 12.99% and a one-year return of 29.73% [2] Group 3 - The fund manager of Huaxia Stable Growth Mixed Fund is Luo Haoliang, who has been in the position for 7 years and 98 days, overseeing a total asset scale of 1.09 billion CNY [3] - During his tenure, the best fund return achieved was 41.66%, while the worst return was -21.48% [3] Group 4 - Huaxia Stable Growth Mixed Fund holds Yinosh as a significant investment, with 930,500 shares representing 4% of the fund's net value, making it the seventh-largest holding [4] - The estimated floating loss for the fund regarding its investment in Yinosh is approximately 3.2381 million CNY [4]

Market Overview - A-shares experienced a collective pullback on January 13, with the Shanghai Composite Index ending a 17-day winning streak, closing down 0.64% [1] - The total trading volume in the Shanghai and Shenzhen markets reached a historical high of 3.7 trillion [1] Sector Performance - Significant declines were observed in various sectors, including commercial aerospace, satellite internet, and military industries, with many stocks dropping over 8% [3] - The large aircraft and military sectors also faced downturns, with several stocks hitting the daily limit down [3] - The commercial aerospace index fell by 6.15%, with a net outflow of 230.78 billion [4] Individual Stock Movements - Over 1,600 stocks rose, with more than 70 stocks hitting the daily limit up, while the commercial aerospace sector saw over 60 stocks limit down or drop more than 10% [3] - Specific stocks such as Aerospace Electronics and Beidou Star Communication experienced significant declines, with many stocks in the sector down by nearly 10% [7] Investment Insights - Analysts suggest that the current market sentiment may indicate a nearing peak, with potential for further structural upward trends despite short-term volatility [12] - Key investment strategies include avoiding speculative risks in popular sectors, focusing on policy-driven industries, and maintaining diversified portfolios to balance risk and return [14] - The emphasis is on sectors with strong earnings growth and valuation alignment, particularly in technology manufacturing and innovative healthcare [14]

证券代码：688710 证券简称：益诺思 公告编号：2026-002 上海益诺思生物技术股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海益诺思生物技术股份有限公司（以下简称"公司"）股票于 2026 年 1 月 7 日、2026 年 1 月 8 日、2026 年 1 月 9 日连续三个交易日内收盘价格涨幅偏 离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板 股票异常交易实时监控细则》有关规定，属于股票交易异常波动的情形。 经公司自查，并书面发函公司控股股东、实际控制人，截至本公告披露日， 公司、控股股东及实际控制人不存在关于公司应披露而未披露的重大事项。公司 目前生产经营正常，生产经营未发生重大变化。 一、股票交易异常波动的具体情况 截至 2026 年 1 月 9 日上海证券交易所交易收盘，本公司股票交易连续三个 交易日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上 海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股 ...

Core Viewpoint - The company announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 30% during the trading days from January 7 to January 9, 2026 [1] Company Status - As of the announcement date, the company, its controlling shareholder, and actual controller confirmed that there are no undisclosed significant matters [1] - The company's production and operations are normal, with no major changes reported [1] Market Activity - The company did not identify any media reports or market rumors that could influence its stock price [1] - During the period of abnormal fluctuation, the company's directors, supervisors, and senior executives did not engage in buying or selling the company's stock [1] Investor Advisory - The company reminded investors to refer to official announcements for accurate information and to invest rationally [1]

格隆汇1月8日丨益诺思(688710.SH)公布，公司于2026年1月8日收到张江生药基地出具的书面告知函。 截至2026年1月7日，张江生药基地通过集中竞价方式减持公司140.98万股股份，占公司总股本的 1.00%。 ...

证券代码：688710 证券简称：益诺思 公告编号：2026-001 上海益诺思生物技术股份有限公司 股东权益变动触及 1%刻度暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海张江生物医药基地开发有限公司（以下简称"张 江生药基地"）持有上海益诺思生物技术股份有限公司（以下简称"公司"） 11,020,753 股，占公司总股本的 7.82%。上述股份均为公司首次公开发行前取得 股份，且已于 2025 年 9 月 3 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 11 月 29 日，公司在上海证券交易所网站披露了《股东减持股份计划 公告》，张江生药基地计划自 2025 年 12 月 22 日至 2026 年 3 月 20 日期间通过集 中竞价交易方式减持其所持有的公司股份数量不超过 1,409,796 股股份，占公司 总股本的比例不超过 1.00%。 公司于 2026 年 1 月 8 日收到张江生药基地出具的书面告知 ...

Core Viewpoint - The announcement indicates a reduction in shareholding by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. in the company, which does not affect the control structure or governance of the company [1] Group 1: Shareholding Changes - Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. reduced its shareholding from 11,020,753 shares to 9,610,957 shares [1] - The percentage of total share capital held by Zhangjiang decreased from 7.82% to 6.82% [1] - The reduction involved a sale of 1,409,796 shares through a centralized bidding transaction, and the plan has been fully implemented [1] Group 2: Impact on Company Structure - The shareholding change does not trigger a mandatory tender offer [1] - There will be no change in the company's controlling shareholder or actual controller [1] - The governance structure and ongoing operations of the company will not be significantly impacted [1]

格隆汇1月8日丨益诺思(688710.SH)公布，公司于2026年1月8日收到张江生药基地出具的书面告知函。 截至2026年1月7日，张江生药基地通过集中竞价方式减持公司140.98万股股份，占公司总股本的 1.00%。 ...

Summary of Key Points Core Viewpoint - The shareholder Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. has completed a share reduction plan, selling 1.4098 million shares of Yinos, which represents 1.00% of the total share capital, at a price range of 43.55 to 55.31 yuan per share, totaling 66.9177 million yuan [1]. Group 1 - The share reduction occurred between December 22, 2025, and January 7, 2026 [1]. - After the reduction, the shareholder holds 9.611 million shares, which is 6.82% of the total shares, down from 11.0208 million shares, or 7.82% prior to the reduction [1]. - This change in equity ownership triggered a change that touches the 1% integer multiple, indicating a significant adjustment in the shareholder's stake [1].

Group 1 - The core point of the article highlights the stock performance of Yinos, which increased by 5.19% to reach a price of 58.18 CNY per share, with a trading volume of 181 million CNY and a turnover rate of 3.57%, resulting in a total market capitalization of 8.202 billion CNY [1] - Yinos is a biotechnology company based in the China (Shanghai) Free Trade Zone, established on May 12, 2010, and listed on September 3, 2024. The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] Group 2 - Among the top ten circulating shareholders of Yinos, a fund under Huatai-PineBridge is noted, specifically the Huatai-PineBridge Healthcare Mixed Fund (470006), which entered the top ten shareholders in the third quarter with 1.1215 million shares, accounting for 1.24% of circulating shares. The estimated floating profit for today is approximately 3.2188 million CNY [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY. Year-to-date returns are 6.72%, ranking 749 out of 8825 in its category, while the one-year return is 36.03%, ranking 3440 out of 8084. Since its inception, the fund has achieved a return of 162.46% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a cumulative tenure of 11 years and 26 days. The total asset scale under his management is 8.093 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -35.19% [2]